Immunology / Virology & Vaccines

#Covid-19 #Immunology / Virology & Vaccines

Sanofi and GSK COVID-19 vaccine delayed

Sanofi and GSK have announced a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase I/II study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Moderna doses first participants in Phase II/III COVID-19 vaccine in adolescents

Moderna has announced that the first adolescent participants have been dosed in the Phase II/ III study of mRNA-1273, its vaccine candidate against COVID-19, in adolescents ages 12 to less than 18. The study is being conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax appoints vaccine industry expert to Board of Directors

Novavax has appointed Margaret McGlynn, to its board as an independent director. She has extensive pharmaceutical industry, vaccine and non-profit experience to her role on the Novavax Board of Directors. “Margie’s deep experience in vaccine commercialisation and understanding of global public health will be invaluable as we move closer to… Read More

#Covid-19 #News

#AMR #CDMO #Covid-19 #Immunology / Virology & Vaccines #RNA

Vaccine nationalism, AMR & CDMO expansion ahead for 2021

The new CPhI report looks ahead to a post-pandemic 2021 with pharma manufacturing capacity and payment structures shifting as new sourcing strategies emerge. It explores the potential implications in 2021 of impending vaccine approvals, a new administration in the White House and a return to dual supply chain strategies. The report… Read More

#Business & Investment #Covid-19 #Editor's Choice #Market Reports #News

#Covid-19 #Immunology / Virology & Vaccines

Less than half of people currently willing to get a COVID-19 vaccine, international survey suggests

A new report on the public’s attitudes towards coronavirus vaccines has revealed that around half of those surveyed (51%) may be willing to get vaccinated next year. Findings from a survey of 13,500 people across 15 countries* in November suggest that fewer would be willing if a vaccine were to… Read More

#Covid-19 #Editor's Choice #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

UC Davis Health joins Novavax in testing new COVID-19 vaccine

Despite the encouraging news of potentially successful COVID-19 vaccine trials, there is not yet an FDA-approved vaccine available. Research into other effective coronavirus vaccines continues, including at UC Davis Health. The health system is expected to launch a stage III clinical trial with the National Institutes of Health (NIH) and… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Oxford vaccine: latest efficacy results released

University of Oxford and AstraZeneca researchers have released a pooled analysis of Phase III trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%. The new study published in the Lancet is the first peer-reviewed publication of Phase III data from studies of… Read More

#Covid-19 #News #Trending News

#Biologics / Biotechnology #Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical

Seppic boosts presence in the human vaccine adjuvant market

Seppic’s Sepivac SWETM vaccine adjuvant for human use can contribute to the development of vaccine solutions to fight seasonal and pandemic influenza, as well as COVID-19. Together with various international partners, Seppic is participating in the global research effort to develop a vaccine solution against COVID-19. These programs are in… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Moderna vaccine: helps antibodies last for three months

In a letter published in the New England Journal of Medicine, Moderna has reported that participants in the Phase I study its mRNA-1273 COVID-19 vaccine candidate, retained high levels of neutralising antibodies for 119 days following first vaccination (90 days following second vaccination). The study was led by the National Institute… Read More

#Covid-19 #News #Trending News

#Biotechnology #Cell therapy #Covid-19 #Gene therapy #Immunology / Virology & Vaccines #Pharmaceutical

Investment banking head offers market outlook for 2021

The Jefferies Healthcare Temperature Check report is now in its third edition and published to coincide with the 11th annual Global Healthcare Conference which was held virtually. Over 500 responses from senior leaders in the sector responded for this year’s report, giving views on both the current state of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #News #Opinion #Trends & Analysis

#Covid-19 #Immunology / Virology & Vaccines

Pfizer vaccine approval: biotech innovation brings positivity for UK private sector

This week has provided hope and optimism that the end of the pandemic is finally in sight, with the UK becoming the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine for widespread use. With almost half of Britain now in Tier 3 and many small businesses facing… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Marketing approval authorisation

Pfizer / BioNTech vaccine approved and available for use in the UK next week

The Pfizer/BioNTech COVID-19 vaccine has been authorised for emergency use by the Medicines and Healthcare Products Regulatory Authority (MHRA). Pfizer and BioNTech recently announced final efficacy analysis in their Phase III study for their mRNA-based COVID-19 vaccine candidate BNT162b2, which showed an efficacy rate of 95% in participants without prior… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax updates on COVID-19 vaccine development

Novavax a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has released an update on its COVID-19 vaccine. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with the company’s proprietary Matrix‑M. “Novavax is in a… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #RNA

SARS-CoV-2 mutations do not appear to increase transmissibility

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers. The analysis of virus genomes from over 46,000 people with COVID-19 from 99 countries is published in Nature Communications. First and corresponding author Dr Lucy… Read More

#Covid-19 #Editor's Choice #News